Ask AI
Advances in Smoldering and NDMM

CE

Advances in Smoldering and Transplant-Eligible Newly Diagnosed Multiple Myeloma: Risk Stratification, MRD-Guided Therapy, and Emerging Treatment Strategies

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 31, 2026

Expiration: January 30, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, James A. Davis, PharmD, BCOP, and Kelley L. Julian, PharmD, BCOP, discuss the evolving management of smoldering and newly diagnosed multiple myeloma (MM), including risk stratification, the role of early treatment and measurable residual disease (MRD)–guided therapy, and emerging frontline quadruplet and immunotherapy-based approaches.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary. 

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with MM do you provide care for in a typical month?​

For those who practice in academic or community settings, please indicate your practice setting:

In my current practice, I am confident in educating patients with high-risk smoldering MM (SMM) on the latest evidence and expert guidance on anti-CD38–based treatment to support informed shared decision-making.

A 75-year-old man with fatigue, weight loss, new back pain, controlled hypertension, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 has been diagnosed with MM and has the following laboratory results:



  • Hemoglobin of 9.5 g/dL

  • Serum creatinine of 1.3 mg/dL

  • Serum M-protein of 3.8 g/dL

  • 50% clonal plasma cells

Which would you recommend as most appropriate?